Back to top
more

Merck & Co. (MRK)

(Delayed Data from NYSE)

$101.88 USD

101.88
10,180,742

-0.44 (-0.43%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $101.93 +0.05 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Merck's Ketruda Gets Positive CHMP Opinion for Lymphoma

Merck & Co., Inc. (MRK) recently announced that its anti-PD-1 therapy, Keytruda, has received positive opinion from CHMP for the treatment of patients with relapsed or refractory classical hodgkin lymphoma (cHL).

    Pfizer's Immunotherapy for Skin Cancer Gets FDA Approval

    Pfizer, Inc. (PFE) and German partner Merck KGaA's investigational cancer treatment, avelumab, was approved by the FDA for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive form of skin cancer.

      Merck Closes Acquisition of Controlling Stake in Vallee S.A

      Merck & Co., Inc. (MRK) has completed the previously announced acquisition of a controlling stake in Vallee S.A., a leading privately held producer of animal health products in Brazil.

        Arpita Dutt headshot

        Why Biotech Stock Gilead (GILD) Could Be a Value Trap

        Gilead's (GILD) valuation looks compelling but is the company really poised for

          Merck's (MRK) Keytruda Gets FDA Nod for Lymphoma Indication

          Merck & Co., Inc (MRK) announced that it has received FDA approval for Keytruda for the treatment of patients with refractory classical Hodgkin lymphoma (cHL) or who had relapsed after three or more prior lines of therapy.

            Celldex (CLDX) Shares Up as Q4 Loss Narrows; Sales Beat

            Celldex Therapeutics, Inc. (CLDX) posted fourth-quarter 2016 loss of 30 cents per share, narrower than both the Zacks Consensus Estimate of a loss of 34 cents and the year-ago loss of 33 cents.

              Immune Design (IMDZ) Q4 Loss In Line; Sales Beat Estimates

              Immune Design Corp.(IMDZ) reported fourth-quarter 2016 loss of 57 cents per share, in line with Zacks Consensus Estimate but narrower than the year-ago loss of 60 cents.

                Ryan McQueeney headshot

                Stock Market Roundup, March 7: SNAP Falls Again, Drug Stocks Dip

                Stocks opened in the red and were down slightly throughout the day on Tuesday. The healthcare sector witnessed some volatility after the release of the Republican plan to replace Obamacare and shares of Snap Inc. fell another 11% just days after its highly-anticipated IPO.

                  Parth Panchal headshot

                  Trump's Tweet Hits Pharma Stocks, Promises Decreased Drug Prices

                  A President Donald Trump tweet promising to increase competition and decrease prices in the drug industry sent pharmaceutical stocks falling on Tuesday.

                    Why Is Merck (MRK) Up 3.7% Since the Last Earnings Report?

                    Merck (MRK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                      Arpita Dutt headshot

                      5 FDA Decisions to Watch Out for in Mar 2017

                      Companies like Merck (MRK) are awaiting key FDA decisions this month.

                        What's in Store for Immune Design (IMDZ) in Q4 Earnings?

                        Immune Design Corp (IMDZ) is scheduled to report fourth-quarter 2016 results after the market closes on Mar 7.

                          Aduro (ADRO) Loss Wider than Expected, Sales Miss in Q4

                          Aduro BioTech, Inc. (ADRO) reported fourth-quarter 2016 loss of 44 cents per share, wider than the Zacks Consensus Estimate of a loss of 38 cents.

                            Arpita Dutt headshot

                            M&As, Pipeline Catalysts to Drive Pharma Sector

                            The sector's fundamentals remain strong -- innovation, mergers and acquisitions (M&As), product approvals and positive data flow should act as catalysts.

                              Agenus (AGEN): What's Ahead for the Stock in Q4 Earnings?

                              Agenus Inc. (AGEN) is expected to report fourth-quarter 2016 results during this month.

                                Arpita Dutt headshot

                                Pharma Industry Outlook - February/March 2017

                                The sector is showing signs of recovery with the NYSE ARCA Pharmaceutical Index gaining 5.1% while the NASDAQ Biotechnology Index is up 7.3%.

                                  Joseph Lu headshot

                                  Bristol Myers' Future Unsure as Carl Icahn Takes Stake

                                  Could Bristol-Myers Squibb Company (BMY) soon be put on the market for sale as activist investor, Carl Icahn, takes interest in the company?

                                    Joseph Lu headshot

                                    Can Carl Icahn Save Bristol Myers Squibb?

                                    Bristol-Myers Squibb Company (BMY) experienced slight growth after Carl Icahn, billionaire activist-investor, reportedly wants to take stake in the company.

                                      The Zacks Analyst Blog Highlights: Merck, Valeant Pharmaceuticals International, Allergan, AstraZeneca and Johnson & Johnson

                                      The Zacks Analyst Blog Highlights: Merck, Valeant Pharmaceuticals International, Allergan, AstraZeneca and Johnson & Johnson

                                        The Zacks Analyst Blog Highlights: Merck, PNC Financial, Express Scripts, VeriSign and Martin Marietta

                                        The Zacks Analyst Blog Highlights: Merck, PNC Financial, Express Scripts, VeriSign and Martin Marietta

                                          What's Driving Lilly's (LLY) Shares after 2016 Decline?

                                          After a rather difficult 2016, share price of pharma giant, Eli Lilly & Company (LLY) has picked up in 2017.

                                            Incyte's (INCY) Beats on Q4 Earnings, Provides 2017 Outlook

                                            Incyte Corporation (INCY) reported fourth-quarter earnings of 15 cents beating the Zacks Consensus Estimate of 14 cents.

                                              Swarup Gupta headshot

                                              Dow 30 Stock Roundup: Coca-Cola, Disney, Visa Beat on Earnings

                                              The Dow endured another volatile week as it bobbed and weaved around record highs.

                                                Agilent (A) Announces Expanded Use of Diagnostic Assay (revised)

                                                Agilent Technologies (A) recently announced the expanded use of its diagnostic assay, Dako PD-L1 IHC 22C3 pharmDx.

                                                  The Zacks Analyst Blog Highlights: Apple, Exxon Mobil, Merck, Pfizer and Intel

                                                  The Zacks Analyst Blog Highlights: Apple, Exxon Mobil, Merck, Pfizer and Intel